Compare Funko Inc (FNKO) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Inovio Pharmaceuticals Inc — how do they compare? Funko Inc trades at $6.43 (market cap $363.97M), while Inovio Pharmaceuticals Inc trades at $1.13 (market cap $112.19M). The key difference: Funko Inc is far larger — about 3.2× Inovio Pharmaceuticals Inc's market cap, and Funko Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| FNKO | INO | |
|---|---|---|
Market Cap | $363.97M | $112.19M |
Volume | 1,422,651 | 3,201,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $2.65 |
52-Week Low | $2.81 | $0.66 |
Typical Hold Time | 33 Days | 43 Days |
Enterprise Value | $584.62M | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $6.525, up 3.41% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue declined to $908.21M in 2025, but Q2 2026 results showed 7% sales growth and improved EBITDA margins. The company maintains a low P/S ratio of 0.38 and reduced debt, while analyst consensus is a 'Hold' with a $7.58 price target.
The outlook is cautiously optimistic; valuation appears attractive, but negative net income and volatile cash flows pose risks. Upside depends on sustained EBITDA growth and execution of the 'Make Culture POP' strategy, while competitive pressures and consumer spending trends remain key watchpoints for investors.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
